Galectin Therapeutics Inc.
$2.35
+1.1%Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -4.9).
Valuation inputs: P/E -4.9, earnings yield N/A, momentum +1.1%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is acceptable (ROE +24.4%, ROIC -1.7%).
Profitability stack: net margin 0.0%, ROE +24.4%, ROIC -1.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +746.1%, momentum +1.1%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Galectin Therapeutics Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Galectin Therapeutics Inc. Fair Value Envelope
No Revenue Data
GALT has not reported any revenue values in the available annual periods.
Galectin Therapeutics Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
GALT has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
GALT has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
GALT has not reported any net profit margin values in the available annual periods.
Galectin Therapeutics Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Galectin Therapeutics Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Galectin Therapeutics Inc. Street Expectations Map
Wall Street analysts project that GALT stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 11.00, with estimates ranging from a low of 11.00 to a high of 11.00.
The consensus 1-year price target stands at 11.00, with estimates ranging from a low of 11.00 to a high of 11.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Galectin Therapeutics Inc. Insider Positioning
During the last 12 months, insiders have purchased $41K and sold $4.05M worth of GALT shares, resulting in $4.01M of net selling activity.
3 Months
0
0.00
568
1.76K
-2K
-$2K
3-6 Months
6.5K
22.93K
311.1K
1.48M
-1.5M
-$1.46M
6-9 Months
200
478.00
463.0K
2.53M
-2.5M
-$2.52M
9-12 Months
6.0K
17.42K
40.0K
44.40K
-27K
-$27K
Top Buyers
Freeman Kevin D
Director
$34K
Eldred Kary
Director
$6K
Lewis Joel
Director, Officer: President And Ceo
$478
Top Sellers
10X Fund, L.P.
10 Percent Owner
$2.17M
Lewis Joel
Director, Officer: President And Ceo
$557K
Jamil Khurram
Officer: Chief Medical Officer
$554K
Callicutt Jack W
Officer: Chief Financial Officer
$384K
Shlevin Harold H.
Director
$341K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $4.01M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
galt Dividend History
Learning Layer
Related Guides
Build conviction on GALT by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.